Skip to main content
Equibles
NAGE logo

NAGE · Niagen Bioscience, Inc. · Webcasts, Transcripts & Audio

Track NAGE — free

Use NAGE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NAGE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.76 -0.03 (-1.08%)
Russell 2000 member Rebalance outlook locked
Market Cap
$241.33M
Shares
79.13M
Volume · Oct 2 1.57M Avg daily vol (3M) 599K

Niagen Bioscience, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Niagen Bioscience, Inc. (NAGE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼1.4% $17.06M −$985,000 '22 Q3 22-11-02 ▲18.2% $21.00M −$1.42M '22 Q4 23-03-08 ▲30.7% $22.56M −$1.90M '23 Q1 23-05-10 ▲21.5% $20.32M −$2.19M '23 Q2 23-08-09 ▲14.3% $19.50M −$959,000 '23 Q3 23-11-08 ▲1% $21.20M $114,000 '23 Q4 24-03-06 ▼1.8% $22.15M −$492,000 '24 Q1 24-05-08 ▲11.9% $22.74M −$15,000 '24 Q2 24-08-07 ▲31.2% $25.58M $1.88M '24 Q3 24-10-31 ▲37.4% $29.12M $7.18M '24 Q4 25-03-04 ▲37.6% $30.48M $5.06M '25 Q1 25-05-07 ▲36.8% $31.12M $3.61M '25 Q2 25-08-06 ▲32.9% $33.99M $4.58M '25 Q3 25-11-04 ▲16.2% $33.84M $4.13M '25 Q4 26-03-04 ▲3.3% $31.47M $6.32M '26 Q1 26-05-06 LATEST ▼4.3% $29.79M $963,000 '26 Q2 26-08-04
Conference
Investor event
2026-08-11
Niagen Bioscience, Inc. (NAGE) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-04
Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript
Positive tone NanoCloud (water-soluble Niagen) FDA lawsuit / motion to dismiss Asia Pacific / Watsons partnership
Revenue
$29.79M
▼ 4.3% YoY
Diluted EPS
$0.01
▼ 75% YoY
Gross margin
64.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-06
Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript
Confident tone Revenue and financial performance Retail distribution strategy Niagen Plus at-home injection launch
Revenue
$31.47M
▲ 3.3% YoY
Diluted EPS
$0.07
▲ 16.7% YoY
Gross margin
63.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-04
Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript
Confident tone Financial Performance and 2026 Guidance FDA Litigation and NMN Regulation Competition and Market Growth
Revenue
$33.84M*
▲ 16.2% YoY
Gross margin
64.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call Transcript
Confident tone Niagen Plus / Clinic & Injection Expansion FDA Decision on NMN / Competitive Landscape Revenue Growth & Financial Performance
Revenue
$33.99M
▲ 32.9% YoY
Diluted EPS
$0.05
▲ 150% YoY
Gross margin
64.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Niagen Bioscience, Inc. (NAGE) Q2 2025 Earnings Call Transcript
Confident tone Parkinson's Drug Pathway Revenue Growth Niagen Plus / Clinic Channel
Revenue
$31.12M
▲ 36.8% YoY
Diluted EPS
$0.04
Gross margin
65.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Niagen Bioscience, Inc. (NAGE) Q1 2025 Earnings Call Transcript
Confident tone Niagen Plus (IV and injectables) E-commerce / Tru Niagen Pharmaceutical pipeline / clinical trials
Revenue
$30.48M
▲ 37.6% YoY
Diluted EPS
$0.06
Gross margin
63.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Niagen Bioscience, Inc. (NAGE) Q4 2024 Earnings Call Transcript
Confident tone E-commerce and Tru Niagen channel Niagen IV and Niagen Plus launch Niagen ingredient business (food and pharmaceutical grade)
Revenue
$29.12M*
▲ 37.4% YoY
Gross margin
62.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Niagen Bioscience, Inc. (NAGE) Q3 2024 Earnings Call Transcript
Confident tone Niagen IV / Niagen Plus launch in clinics E-commerce and TRU Niagen direct-to-consumer Executive transition (new CFO)
Revenue
$25.58M
▲ 31.2% YoY
Diluted EPS
$0.02
Gross margin
63.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Niagen Bioscience, Inc. (NAGE) Q2 2024 Earnings Call
Revenue
$22.74M
▲ 11.9% YoY
Diluted EPS
$0.00
Gross margin
60.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Niagen Bioscience, Inc. (NAGE) Q1 2024 Earnings Call Transcript
Positive tone Scientific Research & Pipeline Retail Distribution Expansion E-commerce & Digital Channels
Revenue
$22.15M
▼ 1.8% YoY
Diluted EPS
$-0.01
Gross margin
60.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Niagen Bioscience, Inc. (NAGE) Q4 2023 Earnings Call Transcript
Positive tone Gross margin and mix Q4 financial performance Partnerships and partner brands
Revenue
$21.20M*
▲ 1% YoY
Gross margin
61.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Niagen Bioscience, Inc. (NAGE) Q3 2023 Earnings Call Transcript
Revenue
$19.50M
▲ 14.3% YoY
Diluted EPS
$-0.01
Gross margin
61.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Niagen Bioscience, Inc. (NAGE) Q2 2023 Earnings Call Transcript
Revenue
$20.32M
▲ 21.5% YoY
Diluted EPS
$-0.03
Gross margin
60.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Niagen Bioscience, Inc. (NAGE) Q1 2023 Earnings Call Transcript
Revenue
$22.56M
▲ 30.7% YoY
Diluted EPS
$-0.03
Gross margin
59.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-08
Niagen Bioscience, Inc. (NAGE) Q4 2022 Earnings Call Transcript
Revenue
$21.00M*
▲ 18.2% YoY
Gross margin
57.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Niagen Bioscience, Inc. (NAGE) Q3 2022 Earnings Call Transcript
Revenue
$17.06M
▼ 1.4% YoY
Diluted EPS
$-0.01
Gross margin
59.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Niagen Bioscience, Inc. (NAGE) Q2 2022 Earnings Call
Revenue
$16.73M
▼ 5.5% YoY
Diluted EPS
$-0.09
Gross margin
60.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Niagen Bioscience, Inc. (NAGE) Q1 2022 Earnings Call Transcript
Revenue
$17.26M
▲ 17.5% YoY
Diluted EPS
$-0.11
Gross margin
61.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-09
Niagen Bioscience, Inc. (NAGE) Q4 2021 Earnings Call Transcript
Revenue
$17.76M*
▲ 15% YoY
Gross margin
61.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-03
Niagen Bioscience, Inc. (NAGE) Q3 2021 Earnings Call Transcript
Revenue
$17.31M
▲ 22.1% YoY
Diluted EPS
$-0.13
Gross margin
61.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Niagen Bioscience, Inc. (NAGE) Q2 2021 Earnings Call Transcript
Revenue
$17.70M
▲ 15.8% YoY
Diluted EPS
$-0.08
Gross margin
61.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Niagen Bioscience, Inc. (NAGE) Q1 2021 Earnings Call Transcript
Revenue
$14.68M
▲ 2.4% YoY
Diluted EPS
$-0.12
Gross margin
62.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-10
Niagen Bioscience, Inc. (NAGE) Q4 2020 Earnings Call Transcript
Revenue
$15.45M*
▲ 18% YoY
Gross margin
61.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Niagen Bioscience, Inc. (NAGE) Q3 2020 Earnings Call Transcript
Revenue
$14.18M
▲ 17.6% YoY
Diluted EPS
$-0.07
Gross margin
59.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Niagen Bioscience, Inc. (NAGE) Q2 2020 Earnings Call Transcript
Revenue
$15.29M
▲ 37.7% YoY
Diluted EPS
$-0.06
Gross margin
59.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Niagen Bioscience, Inc. (NAGE) Q1 2020 Earnings Call Transcript
Revenue
$14.35M
▲ 42.8% YoY
Gross margin
57.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-10
Niagen Bioscience, Inc. (NAGE) Q4 2019 Earnings Call
Revenue
$13.09M*
▲ 44.4% YoY
Gross margin
57.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 webcasts
Key facts CIK 1386570 CUSIP 171077407 13F (30d) 5 filings 4 filers Visit website Investor relations